Boston Partners
CDNA icon

Boston Partners’s CareDx CDNA Stock Holding History

Boston Partners’s Portfolio CDNA Stock Details CDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$24.8M Sell
381,355
-1,556,246
-80% -$70.5M 0.02% 357
2026
Q2 		$55.2M Buy
1,937,601
+54,067
+3% +$1.18M 0.05% 267
2026
Q1 		$32.7M Buy
1,883,534
+981,605
+109% +$18.6M 0.03% 312
2025
Q4 		$17M Buy
901,929
+870,574
+2,777% +$14.6M 0.02% 383
2025
Q3 		$456K Buy
31,355
+9,864
+46% +$141K ﹤0.01% 689
2025
Q2 		$420K Buy
21,491
+34
+0.2% +$604 ﹤0.01% 673
2025
Q1 		$381K Buy
21,457
+158
+0.7% +$3.4K ﹤0.01% 656
2024
Q4 		$456K Sell
21,299
-353,839
-94% -$8.61M ﹤0.01% 652
2024
Q3 		$11.7M Buy
375,138
+350,849
+1,444% +$8.73M 0.01% 386
2024
Q2 		$377K Buy
+24,289
New +$294K ﹤0.01% 681
2023
Q1 		– Sell
-35,099
Closed -$400K – 704
2022
Q4 		$400K Buy
35,099
+24,905
+244% +$369K ﹤0.01% 623
2022
Q3 		$174K Sell
10,194
-273
-3% -$5.86K ﹤0.01% 680
2022
Q2 		$225K Buy
+10,467
New +$290K ﹤0.01% 667

Other funds holding CDNA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Gagnon Securities
Gagnon Securities New York $577M AUM 61.61% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $63.7B AUM 20.33% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Zweig-DiMenna Associates
Zweig-DiMenna Associates New York $1.3B AUM 120.13% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Boston Partners's CDNA Position: Q3 2026 in Review

Boston Partners reduced its CareDx (CDNA) stake by 80% in Q3 2026, selling an estimated $70.5M and leaving 381,355 shares worth $24.8M. The position accounts for 0.02% of the portfolio, ranked #357.

Boston Partners first reported a position in CDNA in Q2 2022 and has held it in 13 quarters since. The position peaked at $55.2M in Q2 2026. 140 funds tracked by Wall St. Rank hold CDNA as of Q3 2026.

  • Boston Partners held 381,355 shares of CareDx worth $24.8M as of Q3 2026.
  • Boston Partners sold 1,556,246 CareDx shares in Q3 2026, an estimated $70.5M.
  • CareDx made up 0.02% of Boston Partners's portfolio in Q3 2026, its #357 holding.
  • Boston Partners first reported a position in CareDx in Q2 2022 and has held it in 13 quarters since.
  • Boston Partners's CareDx position peaked at $55.2M in Q2 2026.
  • 140 funds tracked by Wall St. Rank held CareDx as of Q3 2026.

Based on Boston Partners's 13F filing for Q3 2026, filed 10 Nov 2026.